KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company
January 09, 2023 06:30 ET
|
KemPharm
Matthew R. Plooster named Chairman of the Board of DirectorsRichard W. Pascoe appointed Chief Executive OfficerTravis C. Mickle, Ph.D. transitions to PresidentJoshua Schafer appointed Chief Commercial...
KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)
December 21, 2022 07:30 ET
|
KemPharm
Trial designed as a multi-center, dose-optimizing, double-blind, placebo-controlled, randomized-withdrawal study to evaluate safety and efficacy of KP1077, as well as to assess the symptoms and...
KemPharm Announces Appointment of Christopher Posner as New Independent Director
November 29, 2022 07:30 ET
|
KemPharm
24-year global pharmaceutical executive and current president and CEO of Cara Therapeutics joins KemPharm’s Board of Directors CELEBRATION, Fla., Nov. 29, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc....
KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)
November 18, 2022 07:30 ET
|
KemPharm
Phase 2 clinical trial investigating KP1077 in patients with IH expected to initiate prior to year-end 2022 CELEBRATION, Fla., Nov. 18, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH)...
KemPharm Reports Third Quarter 2022 Results
November 09, 2022 16:05 ET
|
KemPharm
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, November 9, 2022, at 5:00 p.m. ET Significant activities underway for preparation of the arimoclomol NDA...
KemPharm to Report Third Quarter 2022 Financial Results
November 01, 2022 07:30 ET
|
KemPharm
CELEBRATION, Fla., Nov. 01, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization...
KemPharm Supports Niemann-Pick Awareness Month During October and Global Niemann-Pick Awareness Day on October 19th
October 04, 2022 07:30 ET
|
KemPharm
CELEBRATION, Fla., Oct. 04, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization...
KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)
September 28, 2022 07:30 ET
|
KemPharm
SDX administered at single doses of 80 mg and 200 mg was well-tolerated CELEBRATION, Fla., Sept. 28, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty...
KemPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 01, 2022 07:30 ET
|
KemPharm
CELEBRATION, Fla., Sept. 01, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and...
KemPharm Reports Second Quarter 2022 Financial Results and Corporate Updates
August 11, 2022 16:05 ET
|
KemPharm
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, August 11, 2022, at 5:00 p.m. ET Perry Sternberg, Corium, Inc.’s President and CEO, to Participate and Provide...